Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, randomised, placebo-controlled, double-blind, 4-arm parallel-group, 2-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GW642444H (100 administered once daily in the morning via DISKUS [TM] dry-powder inhaler) compared with SEREVENT (salmeterol) (50mcg administered twice daily via DISKUS dry-powder inhaler) and placebo in subjects with moderate COPD [chronic obstructive pulmonary disease].

Next Previous
X
Search
Trial Profile

A multicentre, randomised, placebo-controlled, double-blind, 4-arm parallel-group, 2-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GW642444H (100 administered once daily in the morning via DISKUS [TM] dry-powder inhaler) compared with SEREVENT (salmeterol) (50mcg administered twice daily via DISKUS dry-powder inhaler) and placebo in subjects with moderate COPD [chronic obstructive pulmonary disease].

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vilanterol (Primary) ; Salmeterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline

    • Most Recent Events

    • 11 May 2010 Actual end date (May 2007) added as reported by ClinicalTrials.gov.
    • 11 May 2010 Actual patient number (71) added as reported by ClinicalTrials.gov.
    • 15 Oct 2008 Actual start date changed from Sep 2006 to Nov 2006 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top